Higher-Dose Aspirin for Preeclampsia: Signal Without Certainty

This meta-analysis of head-to-head dose-comparison trials suggests higher-dose aspirin may reduce preeclampsia but cannot confirm it, and flags a placental abruption safety concern relevant to pharmacists advising on prophylaxis.

📅 Journal publication: Aug 2026 (online Jul 10, 2026) · Last updated: Oct 7, 2026

aspirinacetylsalicylic acidantiplateletpreeclampsiapregnancydose comparisonmeta-analysissystematic reviewplacental abruptionwomen's health Women's Health / Reproductive

Background Information

Higher-dose aspirin may lower preeclampsia risk by 48% in high-risk pregnancies.

Preeclampsia is a significant risk in pregnancy, and determining optimal aspirin dosing could improve outcomes for high-risk women. The study found an approximate 48% reduction in preeclampsia risk with higher-dose aspirin, though results were not statistically significant due to small sample size and heterogeneity. While a clinically meaningful effect was observed, it did not achieve statistical significance. Further research is needed to confirm findings and address safety concerns, such as placental abruption. Higher-dose aspirin may reduce preeclampsia risk, but larger trials are needed to confirm efficacy and safety.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Ahmed AM, Goyal R

Citation: Ahmed AM, Goyal R Comparative effectiveness of lower-dose vs higher-dose aspirin for preeclampsia prevention: a systematic review and meta-analysis of randomized controlled trials. AJOG global reports. 2026;6(3):100673. doi:10.1016/j.xagr.2026.100673

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →